Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates Significant Additional Improvement for Patients on Pagoclone

LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persistent developmental stuttering will be presented today at the 47th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), sponsored by National Institute for Mental Health (NIMH) and being held in Boca Raton, Florida. In addition, the presentation will include data from the first three months of open label treatment.

"The progress of the ongoing Phase II open-label phase has been extremely encouraging," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "Our investigators are reporting significant benefit for the vast majority of patients continuing in the open label phase and for several patients, these benefits have been life-changing."

"The results from the open-label extension study reveal that pagoclone is a promising medication for the long-term treatment of stuttering," stated Gerald A. Maguire, M.D., associate professor, department of psychiatry, University of California, Irvine School of Medicine. "As a researcher and a person who stutters, I am excited about the results. Although there is no cure for stuttering, this study suggests that pagoclone holds significant promise as a well-tolerated, effective pharmacologic treatment for stuttering and further studies are indicated."

The open label data demonstrated an improvement in nearly all efficacy measures compared to baseline that was at least double the magnitude seen in the initial 8 weeks of double-blind treatment. During the 8-week, double-blind portion of the study, patients who were randomized to placebo experienced a mean reduction in the percentage of syllables stuttered of 5%. After three months i
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/29/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the CL King 12 ... September 9, 2014 at 12:30 p.m. ET. The conference ... in New York City . ...
(Date:8/29/2014)... 29, 2014 , Industry ... the inaugural Tweetchat taking place in real-time at ... organised by UBM Live , announces the ... a first of its kind global industry-wide Tweetchat ... supply chain, aimed to stimulate conversations on key ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that ... in its catalogue: Needle-Free Delivery: ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html Report ... and commercial prospects What does the future ... brand new report shows you the potential ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18
... 15, 2007 /PRNewswire/ -- Solstice,Neurosciences, Inc. today reported ... of Botulinum Toxin Type B,Injectable Solution (Myobloc(R)) recently ... Disorders Society in,Istanbul, Turkey. , This was the ... of escalating treatment doses of 10,000 Units, 12,500,Units, ...
... Survival Benefit Demonstrated for an AI Over Tamoxifen ... 15 June 2007: Analysis of the entire,population of ... breast cancer can be significantly improved by switching ... 95' (ARNO 95) study, published online in The,Journal ...
Cached Medicine Technology:Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 3Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 4Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 2Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 3Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 4Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 5
(Date:8/29/2014)... The Fibroids Miracle review indicates that this is a new ... and powerful results. It actually claims to be able to ... 12 hours. The method promises to lead to a permanent ... on a 3 step method that has never been revealed ... was in fact created by someone who had an important ...
(Date:8/29/2014)... Daily Gossip reveals in its Stop Sciatica ... method of naturally curing this disease. , The program ... permanent cure in only one week. This is described as ... make huge sacrifices. , Moreover, with this new method ... of sciatica in just 8 minutes. , Interested customers ...
(Date:8/29/2014)... Skmen.com, a famous online supplier of trendy clothes, has unveiled ... the moment, all these mini outfits are offered at discounted ... promotion is September 14. , The company’s senior spokesman ... our hot designs, we have listed some of the best-selling ... stylish ladies to get high quality, fashionable clothes. Many of ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of scalable Asterisk-based ... licensing of its Q-Suite 5.7 software. As a ... been successfully deploying and supporting its ACD and Dialer ... the world for more than a decade. The introduction ... option which complements the widespread deployment of Q-Suite in ...
(Date:8/29/2014)... 2014 Developed as a nod to ... Canada Goose products offer the mobility, durability ... Arctic runways. The company’s Canada Goose Chilliwack bombers ... current market. Additionally, the firm has unveiled its new ... , At present, all high quality Chilliwack bombers are ...
Breaking Medicine News(10 mins):Health News:Fibroids Miracle Review Exposes Amanda Leto’s 3-Step Holistic System 2Health News:Stop Sciatica in 8 Minutes Review Exposes Steven Guo's Complete Sciatica Cure 2Health News:Cheap Sexy Mini Dresses Added To The Product Line Of Skmen.com 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2
... metabolism in weeks , , MONDAY, April 7 (HealthDay News) ... a person at an increased risk for heart disease ... team of French researchers studying the drug,s effect on ... weeks, the rodents, blood sugar levels rose significantly ...
... the use of robotics for minimally invasive cardiac surgery. ... cardiac surgery. With his arrival, BMC has become one ... the only hospital in Boston, to offer robot-assisted minimally invasive ... artery disease (the most common form of heart disease - ...
... LEANDRO, Calif., April 7, 2008 A,tiny lightstick -- ... of,all fatalities from oral cancer, according to the East ... dental group which,recommends that all adults ask their dentists ... procedure with this product will become,as widespread as the ...
... Nutrition 21,Inc. (Nasdaq: NXXI ), a developer ... sugar levels, improve cardiovascular,health, enhance memory and address chronic ... elected to the Company,s Board of Directors,effective April 7, ... Executive Officer of Iceland,Health, Inc. a company acquired by ...
... matter of molecular To Tell the Truth, as scientists ... from those that are imposters. Powerful gene-scanning technology often ... tissue, making it critical for investigators to winnow out ... the April 8 issue of the journal Cancer Cell, ...
... WOODBURY, N.Y., April 7, 2008 CardWorks Servicing, ... servicer,formerly known as Cardholder Management Services, LLC ("CMS"), ... service the new HumanaAdvance,Visa Card. CardWorks will partner ... to offer the HumanaAdvance Visa. Humana,is one of ...
Cached Medicine News:Health News:Antipsychotic Drug Boosts Risk of Heart Disease, Diabetes 2Health News:Robot-assisted minimally-invasive CABG surgery 2Health News:New ViziLite Plus Could Reduce Oral Cancer Fatalities Predicts East Bay's Creative Dimensions in Dentistry 2Health News:Nutrition 21 Elects Mark H. Stenberg to Board of Directors 2Health News:Data-handling technique finds genes to be team players in curbing brain cancer cell growth 2Health News:Data-handling technique finds genes to be team players in curbing brain cancer cell growth 3Health News:CardWorks Named Servicer of Choice for Innovative Credit Card for Healthcare Services 2Health News:CardWorks Named Servicer of Choice for Innovative Credit Card for Healthcare Services 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: